利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

50 条记录 (耗时 0.042 秒)

    Methods for controlling blood pharmacokinetics of antibodies
    11.
    发明授权
    Methods for controlling blood pharmacokinetics of antibodies 有权

    公开(公告)号：US11046784B2

    公开(公告)日：2021-06-29

    申请号：US12295039

    申请日：2007-03-30

    申请人： Tomoyuki Igawa ,  Hiroyuki Tsunoda ,  Tatsuhiko Tachibana

    发明人： Tomoyuki Igawa ,  Hiroyuki Tsunoda ,  Tatsuhiko Tachibana

    IPC分类号： C07H21/04 ,  C07K16/40

    摘要： The present inventors discovered that the half-life in blood of an IgG antibody which is a polypeptide comprising an FcRn-binding domain can be controlled by controlling the surface charge through modification of residues exposed on the surface among residues in the variable regions of the IgG antibody. Antibodies whose half-life in blood had been controlled by the methods of the present invention were confirmed to actually retain the original activity. The methods of the present invention are widely applicable to polypeptides comprising an FcRn-binding domain, such as IgG antibodies, which are recycled via the FcRn salvage pathway regardless of the type of target antigen.

    METHODS FOR CONTROLLING BLOOD PHARMACOKINETICS OF ANTIBODIES
    15.
    发明申请
    METHODS FOR CONTROLLING BLOOD PHARMACOKINETICS OF ANTIBODIES 审中-公开
    用于控制抗体血液动力学的方法

    公开(公告)号：US20090324589A1

    公开(公告)日：2009-12-31

    申请号：US12295039

    申请日：2007-03-30

    申请人： Tomoyuki Igawa ,  Hiroyuki Tsunoda ,  Tatsuhiko Tachibana

    发明人： Tomoyuki Igawa ,  Hiroyuki Tsunoda ,  Tatsuhiko Tachibana

    IPC分类号： A61K39/395 ,  C12P21/02 ,  C07K16/18 ,  C12N15/11 ,  C12N5/06

    CPC分类号： C07K16/40 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/56

    摘要： The present inventors discovered that the half-life in blood of an IgG antibody which is a polypeptide comprising an FcRn-binding domain can be controlled by controlling the surface charge through modification of residues exposed on the surface among residues in the variable regions of the IgG antibody. Antibodies whose half-life in blood had been controlled by the methods of the present invention were confirmed to actually retain the original activity. The methods of the present invention are widely applicable to polypeptides comprising an FcRn-binding domain, such as IgG antibodies, which are recycled via the FcRn salvage pathway regardless of the type of target antigen.

    摘要翻译： 本发明人发现，作为包含FcRn结合结构域的多肽的IgG抗体的血液中的半衰期可以通过在IgG的可变区的残基中修饰暴露于表面的残基来控制表面电荷来控制 抗体。 通过本发明的方法控制血液半衰期的抗体被证实实际上保留了原来的活性。 本发明的方法可广泛应用于包含FcRn结合结构域（例如IgG抗体）的多肽，其通过FcRn补救途径循环，而不管靶抗原的类型如何。

    Structural isomers of sc(Fv)2
    17.
    发明授权
    Structural isomers of sc(Fv)2 有权
    sc（Fv）2的结构异构体

    公开(公告)号：US09493569B2

    公开(公告)日：2016-11-15

    申请号：US11910117

    申请日：2006-03-31

    申请人： Tomoyuki Igawa ,  Hiroyuki Tsunoda ,  Akiko Koga ,  Yasufumi Kikuchi

    发明人： Tomoyuki Igawa ,  Hiroyuki Tsunoda ,  Akiko Koga ,  Yasufumi Kikuchi

    IPC分类号： C07K16/00 ,  C12P21/08 ,  A61K39/00 ,  A61K51/10 ,  C07K16/28

    CPC分类号： C07K16/2866 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/75

    摘要： Structural isomers in sc(Fv)2 compositions of anti-human Mpl antibody and humanized anti-human Mpl antibody were separated, and the obtained structural isomers were cleaved at their linkers to confirm that the structural isomers are of single chain diabody type and bivalent scFv type. In addition, the agonistic activities of these structural isomers were revealed to be significantly different. Furthermore, the present inventors discovered that the content ratio of the structural isomers in sc(Fv)2 compositions could be regulated by altering temperature, modifying lengths of the linkers of sc(Fv)2, or amino acids in their variable regions.

    摘要翻译： 分离抗人Mpl抗体和人源化抗人Mpl抗体的sc（Fv）2组合物中的结构异构体，将得到的结构异构体在其接头上切割，以确认结构异构体是单链双抗体型和二价scFv 类型。 此外，这些结构异构体的激动活性显示出显着差异。 此外，本发明人发现sc（Fv）2组合物中的结构异构体的含量比可以通过改变温度，改变sc（Fv）2的接头的长度或其可变区中的氨基酸来调节。